North America RNAi Therapeutics Market to Grow at a CAGR of 9.0% to reach US$ 598.60 Million from 2020 to 2027

North America RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)); Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Other); Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others); and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals)

Publication Month: Oct 2020 | Report Code: TIPRE00015136 | No. of Pages: 123 | Category: Biotechnology | Status: Published
Covid

The North America RNAi therapeutics market is expected to reach US$ 598.60 million in 2027 from US$ 302.77 million in 2019. The market is estimated to grow with a CAGR of 9.0% from 2020-2027.

Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in North Americaare the key factors driving the growth of RNAi therapeutics. However,high cost of RNAi therapies is the major factor hindering the market growth in North America.

 

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the market during the forecast period.

 

The healthcare systems are engaged in the development and implementation of new RNA technologies to treat a wide range of diseases. A few technologies comprise genome editing technology, RNAi therapeutics, DNA-directed interference technology, and RNA-modifying enzymes. With these advantages of the implementation, the demand for RNA technologies continues to grow. This increasing preference for RNAi therapeutics is a leading factor that the number of start-ups is rising, which will, in turn, have a positive impact on activities related to the development of RNA technologies and drugs. For instance, in August 2020, RNAimmune, Inc., a spin-off start-up of Sirnaomics, Inc. raised about US$ 2.35 million through the rounds of series funding. The start-up is actively engaged in the development of RNA therapies and vaccines. Such developments in RNA technologies will reshape the RNAi therapeutics market during the forecast period.

 

North America has been witnessing growing number of COVID-19 cases since its outbreak. Thus, owing to the rising incidence of COVID-19 in the North America region, there is increase in demand for new therapeutic drugs. Research studies on RNAi therapy for COVID-19 in the region is likely to favor market growth. For instance, the study ‘Prospects for RNAi Therapy of COVID-19’ was conducted in University of Alberta, Edmonton, AB, Canada and was published in July 2020. Thus, growing efforts by pharmaceutical, biotech companies and academic institutes is to treat COVID-19 is likely to propel the growth of the market during the forecast period.

 

Mexico RNAi Therapeutics Market, Revenue and Forecast to 2027 (US$ Mn)

 

NORTH AMERICARNAI THERAPEUTICS MARKET SEGMENTATION

 

By Molecule Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

 

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

 

By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

 

By End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

 

By Country

  • US
  • Canada
  • Mexico

 

Company Profiles

  • Alnylam Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals, Inc
  • Quark
  • Rexahn Pharmaceuticals, Inc
  • Arbutus Biopharma

 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America RNAi Therapeutics Market – By Molecule Type

1.3.2        North America RNAi Therapeutics Market – By Application

1.3.3        North America RNAi Therapeutics Market – By Route of Administration

1.3.4        North America RNAi Therapeutics Market– By End User

1.3.5        North America RNAi Therapeutics Market – By Country

2.           North America RNAi Therapeutics Market –  Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America RNAi Therapeutics Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        RNAi therapeutics Market - North America PEST Analysis

4.3         Expert Opinion

5.           North America RNAi Therapeutics Market -  Key Market Dynamics

5.1         Key Market Drivers

5.1.1        Growing Investments in RNAi Therapies

5.1.2        Rising Prevalence of Chronic Conditions and Infectious Diseases

5.2         Market Restraints

5.2.1        High Cost for RNAi Therapy Development

5.3         Market Opportunities

5.3.1        Significant Number of Pipeline Candidates for Strategic Alliances

5.4         Future Trends

5.4.1        Rising Emphasis on RNA Technologies

5.5         Impact analysis

6.           RNAi Therapeutics Market – North America Analysis

6.1         North America RNAi Therapeutics Market Revenue Forecasts and Analysis

7.           North America RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type

7.1         Overview

7.2         North America RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

7.2.1        North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)

7.3         Small Interfering RNAs (siRNA)

7.3.1        Overview

7.3.2        North America Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)

7.4         MicroRNA (miRNA)

7.4.1        Overview

7.4.2        North America MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

8.           North America RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application

8.1         Overview

8.2         North America RNAi therapeutics Market, By Application 2019 & 2027 (%)

8.2.1        North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3         Genetic Disorders

8.3.1        Overview

8.3.2        North America Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)

8.4         Oncology

8.4.1        Overview

8.4.2        North America Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

8.5         Neurodegenerative Disorders

8.5.1        Overview

8.5.2        North America Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.6         Cardiovascular Disorders

8.6.1        Overview

8.6.2        North America Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.7         Respiratory Disorders

8.7.1        Overview

8.7.2        North America Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.8         Infectious Diseases

8.8.1        Overview

8.8.2        North America Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.9         Renal Diseases

8.9.1        Overview

8.9.2        North America Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.10      Other Disorders

8.10.1     Overview

8.10.2     North America Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

9.           North America RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration

9.1         Overview

9.2         North America RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

9.2.1        North America RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

9.3         Intradermal Injections

9.3.1        Overview

9.3.2        North America Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)

9.4         Pulmonary Delivery

9.4.1        Overview

9.4.2        North America Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

9.5         Intravenous Injections

9.5.1        Overview

9.5.2        North America Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.6         Intraperitoneal Injections

9.6.1        Overview

9.6.2        North America Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.7         Other Route of Administrations

9.7.1        Overview

9.7.2        North America Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

10.        North America RNAi Therapeutics Market Analysis – By End-User

10.1      Overview

10.2      North America RNAi Therapeutics Market, By End-User 2019-2027 (%)

10.2.1     North America RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)

10.3      Diagnostic Laboratories

10.3.1     Overview

10.3.2     North America Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.4      Research and Academic Laboratories

10.4.1     Overview

10.4.2     North America Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.5      Hospitals

10.5.1     Overview

10.5.2     North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

11.        RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1      North America: RNAi Therapeutics Market

11.1.1     Overview

11.1.2     North America: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.3     North America: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.4     North America: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.5     North America: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.6     North America: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.7     North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

11.1.8     US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1       US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2       US: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.8.3       US: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.8.4       US: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.8.5       US: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.9     Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1       Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2       Canada: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.9.3       Canada RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.9.4       Canada: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.9.5       Canada: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.10  Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1    Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2    Mexico: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.10.3    Mexico: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.10.4    Mexico: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.10.5    Mexico: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

12.        Impact of COVID-19 Pandemic on North America RNAi therapeutics Market

12.1      North America: Impact Assessment of COVID-19 Pandemic

13.        Company Profiles

13.1      Alnylam Pharmaceuticals, Inc.

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Arrowhead Pharmaceuticals, Inc

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Quark

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Rexahn Pharmaceuticals, Inc

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Arbutus Biopharma

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)

Table 2.             North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 3.             North America RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 4.             North America RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)

Table 5.             North America RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 6.             North America RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7.             North America RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 8.             North America RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 9.             US RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 10.          US RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          US RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12.          US RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 13.          Canada RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 14.          Canada RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15.          Canada RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 16.          Canada RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 17.          Mexico RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          Mexico RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19.          Mexico RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20.          Mexico RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 21.          Glossary of Terms, RNAi Therapeutics Market

 


LIST OF FIGURES

Figure 1.           RNAi Therapeutics Market Segmentation

Figure 2.           North America RNAi Therapeutics Market Overview

Figure 3.           Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market

Figure 4.           US is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           North America RNAi Therapeutics Market - Leading Country Markets (US$ Mn)

Figure 6.           RNAi Therapeutics Market - North America PEST Analysis

Figure 7.           RNAi Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8.           North America RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9.           North America RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

Figure 10.        North America Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        North America MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        North America RNAi therapeutics Market, By Application 2019 & 2027 (%)

Figure 13.        North America Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        North America Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        North America Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        North America Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        North America Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        North America Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        North America Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        North America Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        North America RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

Figure 22.        North America Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        North America Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24.        North America Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        North America Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26.        North America Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27.        North America RNAi Therapeutics Market, by End-User 2019 & 2027 (%)

Figure 28.        North America Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29.        North America Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)

Figure 30.        North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 31.        North America: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 32.        North America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 33.        North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 34.        US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 35.        Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        Impact of COVID-19 Pandemic in North American Country Markets

 

The List of Companies - North America RNAi Therapeutics Market

  1. Alnylam Pharmaceuticals, Inc
  2. Arrowhead Pharmaceuticals, Inc
  3. Quark
  4. Rexahn Pharmaceuticals, Inc
  5. Arbutus Biopharma
  • It provides understanding of the North America, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
  • It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the North America RNAi therapeutics market.
  • It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the North America RNAi therapeutics market.
  • It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.
TIPRE00015136
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing